CombinatoRx to Present Data for Oncology Programs at American Association for Cancer Research Meeting
Novel Synergistic Mechanisms Discovered for the Treatment of Multiple Myeloma Using CombinatoRx cHTS Technology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 15, 2010 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC. These preclinical studies reinforce the rationale for investigation of A2A and β2AR agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the CombinatoRx combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application.
“Identification of synergistic drugs using combination high-throughput screening”
Posted: April 2010